Frist Cressey Ventures Research
Investment Thesis
Frist Cressey Ventures (FCV) is a healthcare-focused venture capital firm founded in 2016 by former U.S. Senate Majority Leader Bill Frist, M.D. and Bryan Cressey, a pioneer in private equity investing. The firm's mission is to transform healthcare and improve patient lives by partnering with innovative companies addressing systemic healthcare challenges.
FCV's investment thesis combines clinical expertise, policy acumen, and operational excellence. Led by Frist's background as a transplant surgeon and his legislative experience, the firm seeks to invest in companies that:
- Improve quality of care and patient outcomes
- Optimize healthcare economics and system efficiency
- Enhance accessibility and reduce health inequities
- Leverage technology and data to drive innovation
- Address specific healthcare verticals (primary care, specialty care, oncology, behavioral health, etc.)
Fund Profile
FCV operates multiple funds with the firm currently pursuing a $400M Fund IV (as of May 2025). The firm manages approximately $756M in assets under management across its healthcare venture portfolio. The firm focuses exclusively on healthcare innovation, distinguishing itself from generalist VCs through deep sector expertise and unique value-add capabilities.
Stage Focus
FCV invests primarily across:
- Seed: $1M-$5M for companies with early product and initial customer traction
- Series A: $5M-$20M for companies with demonstrated product-market fit
- Growth/Follow-on: Strategic follow-on investments in portfolio companies
The firm's current portfolio reflects active deployment from their latest funds, with 13 investments in 2025 alone.
Check Size
Typical investment ranges:
- Seed stage: $1M-$5M
- Series A: $5M-$20M+
- Follow-on/Growth: Up to $60M+ (as demonstrated by recent Chamber Cardio Series A lead at $60M)
FCV demonstrated significant investing capacity in early 2026, leading a $12M investment in One to One Health and a $60M Series A for Chamber Cardio.
Investment Activity & Momentum
FCV has demonstrated strong deployment activity:
-
Recent major investments (2026):
- January 2026: $12M investment in One to One Health (primary care)
- February 2026: Led $60M Series A for Chamber Cardio (value-based cardiology platform)
- Qualified Health GenAI deployment at University of Texas systems (December 2025)
-
2025 Activity: Made 13 investments during the year, maintaining active deployment from Fund III
-
Fund IV: Pursuing $400M for next fund vehicle (announced May 2025), indicating strong LP confidence and continued growth trajectory
-
Industry Recognition: Named a top venture capital firm by Time Magazine (2025)
Portfolio Composition
FCV's portfolio of 45+ companies spans critical healthcare verticals:
Primary Care & Care Delivery
- One to One Health (employer-sponsored primary care with virtual component)
- Aspire Health (community-based palliative care, 25+ states)
- Main Street Health (rural-focused Medicare Advantage)
- myLaurel (community-based paramedic/nurse care delivery)
- Vim (data/analytics for value-based care)
Specialty & Chronic Disease
- Chamber Cardio (value-based cardiology)
- OneOncology (community oncology platform)
- Thyme Care (oncology navigation and benefits)
- Monogram Health (complex patient in-home care)
- Oshi Health (virtual gastroenterology)
- RightMove (musculoskeletal care)
- 7 Springs Orthopedics (orthopedic/PT services)
Behavioral & Substance Use
- Bicycle Health (virtual opioid use disorder treatment)
- Spero Health (Medication Assisted Treatment provider)
- Blackbird Health (pediatric behavioral health)
- Psych Hub (behavioral health education platform)
- Mindoula/180 Health Partners (behavioral health management)
AI/Technology & Administrative
- Ambience Healthcare (AI documentation and coding)
- CodaMetrix (AI medical coding)
- Carta Healthcare (data abstraction and analytics)
- Qualified Health (AI governance and healthcare-specific agents)
- Spectrum AI (autism care analytics)
- Klara (patient communication/EHR integration)
- DexCare (access optimization platform)
Health Plans & Payer Solutions
- Devoted Health (Medicare Advantage redesign)
- Lynx (payer consumer experience technology)
- Audacious Inquiry (clinical event notifications)
- Praia Health (patient digital health experience)
Infrastructure & Services
- Axuall (clinician credentialing/data network)
- InformedDNA (genetic services access)
- Relode (healthcare recruiting)
- Stratasan (market intelligence)
- Valify (hospital system purchasing analytics)
Team & Expertise
Leadership
Bill Frist, M.D. - Co-Founder & Managing Partner
- Former U.S. Senate Majority Leader (2003-2007)
- Founder of Vanderbilt Multi-Organ Transplant Center
- Performed 150+ heart and lung transplants
- Board service: Select Medical (NYSE: SEM), Teladoc (NYSE: TDOC), Kaiser Family Foundation, Robert Wood Johnson Foundation
- Education: Harvard Medical School (M.D.), Princeton University (B.A.)
Bryan Cressey - Co-Founder & Senior Advisor
- Pioneer in private equity investing
- Co-founder of three major U.S. private equity firms
- 30+ years healthcare investing experience
- Founded addiction treatment center (Above and Beyond) in Chicago
- Education: Harvard Law School (J.D.), Harvard Business School (M.B.A.), University of Washington (B.A. Economics)
Navid Farzad - Managing Partner
- Investor at Morgan Noble Healthcare Partners (Washington, D.C.)
- Private equity experience at Enhanced Healthcare Partners (New York)
- Healthcare investment banking at Lehman Brothers
- Board/observer roles: Bicycle Health, Carta, Dexcare, Vim, Monogram Health, Visana, and 8+ others
- Named 2022 Top 50 in Digital Health honoree by Rock Health
- Education: NYU Stern School of Business (M.B.A.), Loyola University Maryland (B.A.)
Olivia Capra - Partner
- Investor at Kaiser Permanente Ventures and Convey Capital
- VP Barclays Equity Research (6 years, specialty pharmaceutical)
- Co-Founder of The Grind (organization for women/nonbinary healthcare founders)
- Education: London School of Economics (B.Sc. Honors Economics & Social Policy), Chartered Financial Analyst (CFA)
J. Mark Tipps - Partner & COO
- Former partner at Bass, Berry & Sims law firm
- Chief of Staff to Senator Bill Frist in Washington, D.C.
- Deputy Chief Counsel to U.S. Senator Fred Thompson (Chinagate hearings)
- National campaign manager for U.S. Senator Lamar Alexander's 2000 presidential run
- Education: Gustavus Adolphus College (B.A. Accounting/Finance), University of Tennessee (J.D.)
Caroline Young - Head, Partnership Development
- Partnered with Bill Frist on NashvilleHealth (health equity initiative)
- Led Nashville Health Care Council
- Board: Cumberland Pharmaceuticals (NASDAQ: CPIX)
- Education: University of Tennessee (M.S.), University of Mississippi (B.A.)
Investment Team
Matt Schappell - Principal (Joined 2019)
- Investment Banking: Healthcare Technology Group at Ziegler (Chicago)
- Business Development at Universal Health Services subsidiary
- Education: Wheaton College (B.A. Business & Economics with Applied Health Sciences concentration)
Derek Dedeker - Principal (Joined 2022)
- 4 years at Santé Ventures (Austin-based early-stage healthcare VC)
- Investment Banking Senior Analyst, Financial Institutions Group at Citi
- Education: Texas Christian University (B.B.A. Finance)
William Trapnell - Senior Associate (Joined 2021)
- Healthcare Investment Banking at Citi (M&A)
- Education: University of Tennessee (B.S. Accounting with International Business concentration)
Lydia Witty - Investment Associate (Joined 2023)
- Healthcare consulting at AArete (Chicago, payor/provider strategy)
- Nashville native
- Education: Vanderbilt University (B.S. Medicine, Health & Society with Healthcare Economics concentration)
Tommaso Auerbach - Senior Associate (Joined 2023)
- Healthcare multi-strategy platform at Oxeon (early-stage, new company creation, executive search)
- Passionate about AI/human health intersection, care delivery, medical devices, life sciences
- Education: New York University Global Liberal Studies (B.A. Finance & Business Studies)
Value Creation & Support
FCV differentiates itself through comprehensive partnership support beyond capital:
FCV Collective: A unique initiative providing 12-15 senior healthcare executives per year to portfolio companies. These executives bring operational expertise, mentorship, and network access for scaling healthcare businesses.
FCV Forum: An invite-only gathering of healthcare CEOs and cross-industry leaders designed to foster collaboration, share best practices, and drive industry innovation.
Partnership Development Platform:
- CEO support structure tailored to critical growth phases
- Curated relationship-building experiences
- Learning and mentorship opportunities
- Proactive ecosystem connections
- Board support and value creation services
FCV Policy Perspectives: Thought leadership from Senator Frist and team on healthcare policy, regulation, and macro trends.
Strategic Advantages
- Unique Policy & Clinical Access: Senate experience combined with clinical expertise creates unparalleled ability to navigate healthcare regulation and reimbursement
- Operational Expertise: Team includes CFOs, COOs, healthcare leaders from major health systems
- Network Effects: Deep relationships across payors, providers, policy makers, and healthcare executives
- Sector Focus: Pure healthcare focus (no diversification) allows for deep expertise and pattern recognition
- Multiple Fund Vehicles: Ability to deploy capital across Seed through Growth stages
- Executive Talent: Access to senior operational talent through FCV Collective
Geographic Focus
Primary: United States (with concentration in Southeast/Nashville region) Secondary Markets: NYC (office), broader U.S. focus for national healthcare solutions
Portfolio companies operate across all 50 states, reflecting the firm's focus on national healthcare platforms rather than regional ones.
Decision Making & Process
- Decision Structure: Partnership-based with investment committee involvement
- Timeline: Typically 4-8 weeks from initial meeting to decision for series A investments
- Warm Introductions: Preferred but not required for founder outreach
- Lead Tendency: Regularly leads rounds, often takes board seats
- Board Involvement: Active board participation with regular engagement
Anti-Thesis
FCV explicitly avoids:
- Non-healthcare focused investments
- Purely consumer health/wellness products (unless healthcare system integrated)
- Healthcare services with limited innovation or scaling potential
- Businesses with misaligned incentives to patient outcomes
Founder Preferences
FCV seeks founders who:
- Have deep healthcare industry experience or clinical backgrounds
- Demonstrate genuine passion for improving patient outcomes
- Understand healthcare's regulatory and reimbursement complexity
- Possess operational excellence and scaling discipline
- Can articulate clear thesis on how their solution improves care economics
- Bring complementary skills (tech founder + healthcare operator ideal)
Current Fund Status
- Fund III: Actively deploying (recent activity January-February 2026)
- Fund IV: $400M vehicle in fundraising (announced May 2025, 115 LPs committed as of filing)
- Status: Actively sourcing and investing; fund IV indicates strong momentum and LP confidence
Notable Exits & Returns
While exit data is limited in public filings, portfolio includes:
- Portfolio companies ranging from seed-stage through mature platforms with $30M-$50M+ ARR
- Companies operating at national scale (25+ states to all 50 states)
- Some portfolio companies approaching IPO readiness
Recent Recognition
- Named top venture capital firm by Time Magazine (2025)
- Multiple portfolio companies winning industry awards
- Active media presence with Bill Frist contributing healthcare policy commentary to major publications